Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Sanofi gets US okay for $270,000 blood disorder drug Cablivi
It is the first US drug approval for Sanofi’s rare blood disorders franchise, which also includes haemophilia drugs acquired along with Biogen spin-off Bioverativ in 2018.
Latest news
-
Pfizer closes on EU approval of lung cancer drug Vizimpro
The two new biosimilars will join products from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit in an assault on AbbVie’s market share for the
-
GSK and Sanofi join Finland's 500,000 genomics study
Service. It also has seven other pharmaceutical companies on board, including Biogen, AbbVie, Celgene, Genentech, Pfizer, MSD and AstraZeneca.
-
Researchers reverse Alzheimer’s memory loss in mice
Meanwhile, the next big hope in the pharma industry’s late stage pipeline for Alzheimer’s is Biogen’s aducanumab. ... Many investors hope to see interim data from Biogen’s phase 3 study of the drug this year, however the company refuses to
-
Rising economic risk casts shadow on Davos meeting
The latter including input from Biogen CEO Michel Vounatsos, whose company has two of the few remaining drug candidates which could provide a breakthrough against the disease.
-
Pfizer takeover rumour ignites Amarin shares
Analysts are now betting that Biogen could be the next company to announce a deal, as it is becoming increasingly reliant on a pipeline focused on Alzheimer’s disease, a
More from news
Approximately 98 fully matching, plus 255 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
only other SMA treatment available, Biogen’s Spinraza.
-
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
However, research from RAND and the University of Southern California that was sponsored by Biogen has found that several European countries lack the capacity to rapidly move a disease-modifying treatment
-
Deal Watch October 2018
Samsung Bioepis is a joint venture between Samsung and Biogen Idec; the latter recently (June 2018) invested $700m to bring its stake in the jv to 49.9%.
-
No incentive for a cure
to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to.
-
Deal Watch January 2018
Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound
More from intelligence
Approximately 1 fully matching, plus 35 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Leukemia Therapeutics Treatment Market Latest Innovations, Drivers and Industry Key Events 2015 - 2025
Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals, Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer and others.
-
Leukemia Therapeutics Treatment Market Revenue, Opportunity, Segment and Key Trends 2015 - 2025
Request to View TOC@ . Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals, Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb,
-
Leukemia Therapeutics Treatment Market Prophesied to Grow at a Faster Pace by 2025
Request Report for TOC @ . Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals, Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers
-
Healthcircle
Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.
-
Attigo (part of the Mednet Group)
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
More from PMHub
Approximately 1 fully matching, plus 14 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Digital Account Director
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Project Manager/ Account Manager
-
Salary TBC
Subscribe to our email news alerts
- Lighthouse Medical Commuications US appoints Lisa Druce as its new Managing Partner
- GW Pharma's cannabis-based medicine to be tested in dementia
- International Childhood Cancer Day 2019
- AZ says dropping MedImmune will help ‘streamline’ its R&D
- Merck puts prostate cancer firmly in Keytruda’s sights
- Biosimilar Herceptin helps Roche gain new Perjeta recommendation
PMHub
Complete HealthVizion
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...
Latest intelligence
- International Childhood Cancer Day 2019
- The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
- Immuno-oncology in 2019: the rapid evolution continues
- Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
- Mixing up Focus Groups
- A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Quick links
Infographics
